VAPO Vapotherm
WatchlistVapotherm News
Vapotherm Educates Over 8,000 Clinicians in Respiratory Care Month
Piper Sandler Maintains Underweight on Vapotherm, Lowers Price Target to $1
Piper Sandler analyst Jason Bednar maintains Vapotherm (NYSE:VAPO) with a Underweight and lowers the price target from $2 to $1.
Vapotherm Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/09/2023 -57.81% Piper Sandler $2 → $1 Maintains Underweight 02/13/2023 -78.9% Piper Sandler $1 → $0.5 M
Earnings Call: Vapotherm Q3 2023 Results Reveal 18% Revenue Growth, Targets Cash Flow Positivity by Mid-2024
BTIG Reaffirms Their Hold Rating on Vapotherm (VAPO)
Vapotherm Cuts FY23 Revenue Guidance From $70M-$73M To $69M--$71M
Vapotherm Cuts FY23 Revenue Guidance From $70M-$73M To $69M--$71M
Vapotherm GAAP EPS of -$2.38 Misses by $0.18, Revenue of $15.2M Misses by $1.52M
Earnings Flash (VAPO) VAPOTHERM Posts Q3 Revenue $15.2M, Vs. Street Est of $16.7M
04:10 PM EST, 11/08/2023 (MT Newswires) -- Earnings Flash (VAPO) VAPOTHERM Posts Q3 Revenue $15.2M, vs. Street Est of $16.7M
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. • Evotec (NASDAQ:EVO) is estimated to report quarterly loss at $0.05 per share on reve
Earnings Outlook For Vapotherm
Vapotherm (NYSE:VAPO) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here's what investors need to know before the announcement.Analysts estimate that Vapotherm will rep
Vapotherm To Report Third Quarter 2023 Financial Results
EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the
Biggest Short Squeeze Stocks Of The Week: Two Biotech Stocks Move Up To Top The List
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move.High short interest and steep borrowing costs are among the
(SEC Amendment) Vapotherm(VAPO.US) Director Buys US$117.34K in Common Stocks
$Vapotherm(VAPO.US)$ Director Arnerich Anthony L. purchased 37,750 shares of Common Stocks on Aug 30, 31, 2023 at an average price of $3.1083 for a total value of $117.34K.Source: Announcement What is
Computational Fluid Dynamics (CFD) Modeling Further Distinguishes Vapotherm High Velocity Therapy From Generic High Flow Cannulas
Vapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of
GME, SSL and GRTS Are Among Pre Market Gainers
The FDA Approves IDE for ReGelTec's Pivotal Study of HYDRAFIL for Chronic Low Back Pain Due to Degenerative Disc Disease
ReGelTec, Inc., announced that the U.S. Food and Drug Administration has approved an IDE for the company's pivotal study to support premarket approval of its HYDRAFIL System. The HYDRAFIL System contains an
Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids
Vapotherm Inc (NASDAQ:VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an
Vapotherm High Velocity Therapy Outperforms in Children With Asthma
Breakthrough in Pediatric Asthma Care: Vapotherm's HVNI Reduces Hospital Stay and Escalation Needs, Reveals ERS 2023 Study
Vapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat p
Pilot Study Demonstrates Vapotherm HVNI Technology Is More Effective Than Standard Oxygen Therapy for Treatment of Acute Asthma in Children
Vapotherm, Inc. (NYSE: VAPO) today announced the presentation of an Investigator-initiated clinical trial, "High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial" at the European Respiratory Society International Congress 2023.